The Clinician’s Toolkit for Measuring How Well Tests Work
India bears ¼ of the global cervical cancer burden.
Rural districts lack Pap smear infrastructure — so the government promotes VIA (Visual Inspection with Acetic Acid).
A community health worker screens 1000 women with VIA. Results are compared against colposcopy-directed biopsy.
| Test | Sensitivity | Specificity |
|---|---|---|
| VIA | 80% | 85% |
| Pap Smear | 60% | 95% |
“VIA is more sensitive — isn’t it the better test?”
It depends on what you need the test to do.
Standard layout: Index test in rows, gold standard in columns.
Convention Alert
FP is in the top-right corner (test +, disease −). Most textbooks, NEET PG, and USMLE follow this layout.
Sensitivity (True Positive Rate)
\[\text{Sens} = \frac{TP}{TP + FN}\]
“Of patients WITH disease, how many test positive?”
. . .
VIA: \(\frac{40}{50} = 80\%\)
Pap: \(\frac{30}{50} = 60\%\)
. . .
Use: Screening — don’t miss cases
Mnemonic: SnNOut — Sensitive test, Negative result, rules Out
Specificity (True Negative Rate)
\[\text{Spec} = \frac{TN}{FP + TN}\]
“Of patients WITHOUT disease, how many test negative?”
. . .
VIA: \(\frac{808}{950} = 85\%\)
Pap: \(\frac{902}{950} = 95\%\)
. . .
Use: Confirmation — don’t overdiagnose
Mnemonic: SpPIn — Specific test, Positive result, rules In
Positive Predictive Value
\[PPV = \frac{TP}{TP + FP}\]
“If test positive, what’s the chance of disease?”
. . .
VIA PPV = \(\frac{40}{40 + 142}\) = 22%
Pap PPV = \(\frac{30}{30 + 48}\) = 38%
At 5% prevalence, 78% of VIA positives are false alarms!
Negative Predictive Value
\[NPV = \frac{TN}{FN + TN}\]
“If test negative, what’s the chance of no disease?”
. . .
VIA NPV = \(\frac{808}{10 + 808}\) = 98.8%
Pap NPV = \(\frac{902}{20 + 902}\) = 97.8%
Both excellent for ruling out.
The Key Insight
Sensitivity and specificity are test properties. PPV and NPV depend on prevalence — the same test behaves differently in different populations!
\[LR^+ = \frac{\text{Sensitivity}}{1 - \text{Specificity}}\]
\[LR^- = \frac{1 - \text{Sensitivity}}{\text{Specificity}}\]
| Test | LR+ | LR− |
|---|---|---|
| VIA | 5.3 | 0.24 |
| Pap | 12.0 | 0.42 |
| LR+ Value | Interpretation |
|---|---|
| > 10 | Strong rule-in |
| 5 – 10 | Moderate rule-in |
| 2 – 5 | Weak evidence |
| LR− Value | Interpretation |
|---|---|
| < 0.1 | Strong rule-out |
| 0.1 – 0.2 | Moderate rule-out |
| 0.2 – 0.5 | Weak evidence |
Key insight: Pap+ is more convincing (LR+ = 12 → strong rule-in), but VIA− is more reassuring (LR− = 0.24 < 0.42).
This quantifies SnNOut / SpPIn precisely.
| AUC Range | Discrimination | Clinical Analogy |
|---|---|---|
| 0.90 – 1.00 | Excellent | Troponin for MI |
| 0.80 – 0.90 | Good | GeneXpert for TB |
| 0.70 – 0.80 | Fair | CRP for infection |
| 0.60 – 0.70 | Poor | ESR for inflammation |
| 0.50 | None | Coin flip |
Practical Meaning
AUC = 0.87 means: pick one random diabetic and one random non-diabetic — there’s an 87% chance the diabetic has a higher fasting glucose.
| Clinical Scenario | Priority | Reason | Indian Example |
|---|---|---|---|
| Community screening | HIGH Sensitivity | Don’t miss cases | VIA for cervical cancer |
| Confirming diagnosis | HIGH Specificity | Don’t overdiagnose | Biopsy after VIA+ |
| Ruling out danger | HIGH Sensitivity | FN = patient sent home | D-dimer for PE |
| Low prevalence | HIGH Specificity | Reduce false positives | HIV screening |
| Toxic treatment | HIGH Specificity | FP → unnecessary harm | Chemo based on biopsy |
SnNOut / SpPIn: Sensitive Negative rules Out. Specific Positive rules In.
Setting: Rural PHC in Bihar, TB prevalence 3%
Test: GeneXpert MTB/RIF — Sens 98%, Spec 99%
Why GeneXpert works at low prevalence:
. . .
The Specificity Secret
99% specificity means only 10 false positives per 1000 non-diseased patients. Compare to 90% specificity → 100 FPs. High specificity protects PPV at low prevalence.
The programme logic: In rural India where follow-up is unreliable, VIA + same-day cryotherapy catches 80% of precancers in a single visit. Test selection depends on healthcare context, not just statistics.
2×2 table — index test in rows, gold standard in columns, FP in top-right
Sensitivity & specificity are test properties; PPV & NPV depend on prevalence
Low prevalence destroys PPV — even good tests produce mostly false positives
Likelihood ratios are prevalence-independent: LR+ > 10 = strong rule-in, LR− < 0.1 = strong rule-out
ROC curves show the full sensitivity-specificity trade-off; AUC summarises discrimination
Two-step strategy — screen (high sensitivity) then confirm (high specificity)
Context matters — VIA was chosen for India not for best PPV, but for the “see and treat” model
Videos:
Textbooks:
Biostatistics for Clinicians | Module 5